Studies have shown that endogenous RAC1P29S in BRAFV600E mutant melanoma is related to early resistance to BRAF inhibitors, and silencing RAC1P29S expression can restore the sensitivity of cells to BRAF inhibitors (14). Here, BRAF is linked to melanoma.